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There is evidence to suggest that receptors with seven 
transmembrane domains can exist in G protein- 
activating conformations. It is not known how many 
activated receptor forms exist for each receptor. 
Furthermore, if there are multiple forms, does the 
chemical structure of the agonist determine which form 
dominates, and therefore, which response pathway is 
activated? This latter scheme is referred to as 
agonist-receptor trafficking, and is discussed in this, 
the second of two articles by Terry Kenakin. One way to 
approach these questions is to study receptors that 
couple to more than one G protein and, in essence, to 
try to allow the G protein to indicate the receptor state. 
It is known that in many physiological, and heterologous, 
expression systems, agonists can activate numerous 
biochemical-response pathways. In general, there are 
two possible mechanisms for such pleiotropic agonist 
responses: one depends on the strength of the original 
signal, and the second results from selective G protein 
activation (Box 1). 
The activation of different biochemical pathways in 
cells by different agonists acting on the same receptor 
does not in itself constitute vidence for multiple active 
receptor states ince there are many biochemical path- 
ways in cells that can trigger the activation of other path- 
ways. For example, activation of bradykinin receptors in 
cultured rat mesangial cells causes adecrease incAMP, 
but through a pathway involving phospholipase C 
(Ref. 1). Furthermore, the entry of Ca 2÷ from the extracel- 
lular space is known to trigger the release of intracellular 
Ca 2÷ from internal stores. In addition, it is now known that 
the activation of G proteins by receptors eleases two sets 
of active effectors: the a subunit and the 13~/subunits. 
Under these circumstances, the measurable r sponse to 
an agonist may depend upon the types of effector present, 
that is, one cell may contain effectors responsive to the 13~/ 
subunits and one may not. 
Differential strength of signalling 
A general mechanism whereby agonists can variably 
activate multiple cellular pathways i  through differences 
in the strength of the stimulus. This can be shown in a simu- 
lation where biochemical cascades are modelled by suc- 
cessive hyperbolae. Given two sequential hyperbolic 
functions, the product of one feeding into the other, it is 
a mathematical onsequence that he result of the multiple 
function will be an amplification ofthe product of the first 
function. Therefore, if one second messenger triggers the 
activation of a second measurable r sponse, the magni- 
tude of the second response necessarily will be more sensi- 
tive to the strength of the original receptor signal. Under 
these circumstances, there are numerous possible combi- 
nations of agonists of differing intrinsic efficacy that could 
produce measurable amounts of one of the hyperbolic 
products but not the other. For example, the effects of two 
agonists on sequential hyperbolic response systems are 
represented in Fig. 1. Agonist I has a high efficacy and 
produces measurable effects from both stimulus cascades. 
However, Agonist II has only 3% of the intrinsic efficacy 
of Agonist I and produces a measurable amount of the 
second (amplified) cascade product, but extremely ow 
amounts of the first. Thus, it would appear that Agonist I 
produces a pleiotropic response while Agonist II pro- 
duces only a single response. These data would not be evi- 
dence for differential production of receptor active states 
by the two agonists but rather would be the result of dif- 
ferential strength of signals and selective dissection of the 
stimulus-response cascade in the cells. 
A useful method to delineate such mechanisms is to 
observe the effect of signal decline of the responses to an 
agonist of high efficacy. For example, Costa and col- 
leagues have shown that the opioid receptor agonist 
[DAlaZ--DLeuS]enkephalin (DADLE) produces stimulation 
of high-affinity GTPase and also inhibition of basal 
adenylate cyclase in NG 108-115 cells 2. Upon decline of 
the receptor stimulus through receptor alkylation, itwas 
shown that he least sensitive response (GTPase response) 
was eliminated and the most sensitive response re- 
mained. Thus, by manipulation f receptor number, ago- 
nists could produce multiple or single biochemical 
responses 2. Similarly, agonists of differential intrinsic 
efficacy could do the same: an agonist of high efficacy 
would activate multiple biochemical cascades while an 
agonist of low efficacy would only activate the most 
sensitive cascade. This would not constitute vidence for 
selective receptor active states for the two agonists. 
Receptor-G protein systems 
A variant of this idea applies to receptor-G protein sys- 
tems. If agonism is a function of selective affinity of an 
agonist for the active receptor state (R*) over the inactive 
receptor state (R) as in the two-state theory for ion 
channels, then an array of agonists could be tested with 
varying differential ffinity for R and R* (denoted by the 
factor R where ~ = affinity for R* / affinity for R). Concen- 
tration-response curves for the chemical reaction between 
receptors (activated by three agonists) and a fixed amount 
of G protein are shown in Fig. 2a. All three agonists pro- 
mote ternary complex formation but not to the same 
extent, i.e. the agonist hat produces the highest level of 
R* is most efficient at ternary complex formation. Thus, 
the value of c~ dictates the location of the concen- 
tration-response curve between steady-state amounts of 
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activated receptor and G protein. If this reaction was fixed 
at a given receptor level (i.e. JR] - 5) the quantity of the 
G protein would exceed that of the receptor. This situation 
is apparently seen in a number of physiological systems, 
although the imposition of cellular factors controlling 
receptor-G protein access (for example, cytoskeletal 
elements) make the use of these stimates doubtful 3.With 
values of [R] = 5 and [G] = 10, the agonist hat produces 
the least amount of R* (~x = 1.2) produces the least amount 
of ternary complex (Fig. 2b). 
These three different agonists produce very different 
amounts of ternary complex yet these involve the identi- 
cal active state of the receptor. The difference in the 
amount of ternary complex arises from the fact that dif- 
fering amounts of R* exist at equilibrium in the presence 
of the agonist. This has been observed experimentally 
(Fig. 2c). Graded concentrations of acetylcholine produce, 
as expected, graded quantities of ternary complex with 
muscarinic acetylcholine r ceptors and G proteins in ven- 
tricular membranes 4. The same effect is seen with maxi- 
mally saturating concentrations of agonists of differing 
intrinsic efficacy. For example, in cardiac membranes 
there is a differential production of maximal amounts of 
ternary complex produced by the agonists carbachol, 
pilocarpine and McNA343 (Fig. 2d) 4. Hence, from both 
simulations and experimental data, it can be seen that 
even with one receptor activating a single G protein and 
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Fi B. 1. First and second responses of two agonists (I and II) of differing efficacy according to two hyperbolic stimulus-response functions, a: The two 
hyperbolic responses according to E 1 = S/(S+ 1)(Function 1 ) and E 2 = S/(S+ 0.1)(Function 2)where E 1 and E z are the first and second responses, respectively, 
and S is the concentration of stimulus, b: Agonist I produces strong responses (E 1 and E 2) from both Function 1 and 2. c: Agonist II has 3% of the efficacy of 
Agonist I therefore the initial response E 1" according to Function 1 is nearly negligible; however, the amplification of E 1' by Function 2 produces a measur- 
able secondary response (E~') to this agonist. 
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Fig. 2. Effects of differential affinity of activated receptor for G proteins, a: Concentrations of ternary complex (ARG) formed with saturating concentration 
of agonists. ~ = affinity for the active receptor state (R*)/affinity for the inactive receptor state (R). Curves are shown for an agonist where c~ = 10 (@), 
c~ = 5 (©) and ~ = 1.2 ([~). Inset: A, agonist; G, G protein; K, equilibrium constant, b: Concentration-response curves for ternary complex formation for the 
three agonists. [R] = 5 M. C: Differential production of ternary complex between carbachol, muscarinic acetylcholine receptors, and (3 protein as a function 
of carbachol concentration. Data from Ref. 4. d: Differential production of maximal amounts of ternary complex formation between the muscarinic acetyl- 
choline receptor agonists carbachol, pilocarpine and McNA343, muscarinic acetylcholine receptors and G protein. Data from Ref. 4. 
producing a single active receptor state, apparently 
different responses from different agonists can result. 
Receptor promiscuity overlaps into active 
receptor states 
There is a fundamental increase in complexity of the 
behaviour of receptors when they can activate multiple 
G proteins in membranes. There are examples of this type 
of behaviour in physiological nd reconstituted systems s. 
However, while receptor promiscuity can occur, it should 
be put into stoichiometric perspective. The probability 
that any biochemical reaction can go forward is controlled 
by the magnitude ofthe equilibrium dissociation constant 
of the resulting complex and the relative molar quantities 
of the reactants. Receptors and individual G proteins have 
intrinsic association constants and it is a logical assump- 
tion that receptors differentiate b tween different G pro- 
teins to offer selectivity at this level of signalling. Promis- 
cuous receptor coupling is becoming a more commonly 
observed phenomenon asmore receptors are studied in 
heterologous expression systems under conditions of 
high levels of receptor expression s . Whether eceptor 
promiscuity occurs physiologically orbecause of aberrant 
stoichiometry is not relevant to the discussion of the basis 
of agonist efficacy. The point of this discussion is that 
when receptor promiscuity does occur, it can sometimes 
be used as a 'looking glass' into receptor activation states 
and indicate whether the receptor exists in a single acti- 
vated state or one that changes with the type of agonist. 
In systems where multiple ternary complexes are 
formed by agonists, it theoretically should be possible to 
test whether certain agonists electively favour receptor 
coupling to one G protein over another (i.e. agonist raf- 
ticking). However, the influence of strength of signal must 
be considered here as well. For example, a single activated 
state of the receptor may have a high affinity for one 
G protein and a lower affinity for another. An agonist of 
high efficacy that produces a large amount of the acti- 
vated receptor may produce nough activated receptor to 
couple to both G proteins while an agonist of low efficacy 
may promote coupling only to the most efficiently 
coupled G protein. Under these circumstances, it would 
appear that the former agonist activates two G proteins 
while (the latter agonist) activates only one. For example, 
the activation of the G proteins G s and G i has been inves- 
tigated in Chinese hamster ovary (CHO) cells transfected 
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with human c~2-adrenoceptors by adrenaline and 
oxymetazoline 6 (Fig. 3). When each G protein response is
isolated by respective treatment ofcells with pertussis or 
cholera toxin, adrenaline activates both G~ and G i while 
oxymetazoline activates only G i. This may suggest that 
oxymetazoline produces a unique activated receptor form 
that couples only to G i while adrenaline produces another 
form (or two forms) that activate(s) both G proteins. How- 
ever, it also is possible that the strength of signal 
phenomenon may be the crucial factor: oxymetazoline 
may produce less activated receptor thereby producing 
coupling only to the most susceptible G protein. 
Reversal of agonist potency 
The most easily interpretable evidence of agonist- 
specific active receptor states would theoretically be 
obtained from actual reversals of relative agonist potency 
with different G proteins. Under these circumstances, the 
selectivity would not result from a simple case of high ver- 
sus low efficacy agonists, but rather one agonist would be 
a strong promoter of one complex and the other agonist 
would be a strong promoter of the other complex (Fig. 4a). 
There are selective xamples of this phenomenon. 
The production of cAMP and inositol phosphate me- 
diated by a splice variant of the pituitary adenylate cyclase 
activating polypeptide (PACAP) receptor t ansfected into 
LLC PK1 cells has been measured 7 (Fig. 4b). PACAPl_27 is 
more active than PACAPl_38 for the production of cAMP, 
but it is considerably less active in the production of inosi- 
tol phosphates. This reversal of potency suggests that a 
simple difference in the strength of signal cannot account 
for the differential G protein activation. 
Another example of such a reversal in an expression 
system is the Drosophila octopamine-tyramine receptor in 
CHO cells . This receptor mediates attenuation ofcAMP 
and Ca 2÷ transients via different coupling mechanisms. 
A clear difference inagonist potency is seen for these two 
responses. Whereas tyramine is almost two orders of 
magnitude more potent than octopamine for cAMP attenu- 
ation, octopamine is more potent han tyramine when the 
kinetics of Ca 2+ responses are compared s. 
One method of delineating agonist trafficking effects is 
to compare the relative fficacies of agonists in receptor 
systems. Agonist activity is a composite of the properties 
of affinity and intrinsic efficacy and the efficacy com- 
ponent is directly related to the nature of the G protein 
coupled to the receptor. Therefore, a measure of relative 
efficacy is a measure of a receptor-G protein interaction 
and not just a receptor 9,1°. For example, ithas been found 
that the two dopamine receptor agonists quinpirole and 
3-(3-hydroxyphenyl)-N-n-propylpiperidine [(+)3-PPP] dem- 
onstrate reversed relative efficacies for activation of 
dopamine D2 receptors in rat anterior pituitary and stri- 
atum 11 (Fig. 4c). The simplest account for such a reversal 
of potency for a single receptor isthat he receptor ispres- 
ent in a milieu of different G proteins in each tissue and 
that the respective agonists produce activated receptor 
complexes of differing sensitivity to each G protein. 
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Fig. 3. Selective activation of G proteins G i and G s by agonist-activated c~- 
adrenoceptors in transfected Chinese hamster ovary cells. The effect of 
adrenaline is shown in the presence of pertussis and cholera toxin {@ and 
HD, respectively), and the effect of oxymetazoline is shown in the presence 
of pertussis and cholera toxin (© and [B, respectively). Data from Bef. 6. 
Selective agonist blockade 
An increasingly observed phenomenon is the differen- 
tial sensitivity of different agonists to antagonists for the 
same receptor. For example, this has been observed for 
the tachykinin NK 1 receptor agonists ubstance P and an 
analogue septide with the antagonist RP67580 (Ref. 12), 
and other agonists that are analogues of substance P with 
a number of antagonists 13,~4. 
Receptor heterogeneity 
The most straightforward explanation for this behaviour 
is that he agonists activate a heterogeneous receptor popu- 
lation in the tissue with differential ffinity for the antag- 
onist. In tissues, receptor heterogeneity s almost always a 
possibility, and thus it is extremely difficult o differentiate 
between a mixture of receptors and a mixture of receptor 
coupling. This situation can be somewhat clarified in an 
expression system where a single receptor protein is 
expressed in a surrogate cell. Under these circumstances, 
the postulate of heterogeneous receptors can be excluded 
and the mechanism of differential blockade of agonists 
can be explored. In COS cells transfected with the NK 1 
receptor and stimulated with either substance P (Fig. 5a) 
or septide (Fig. 5b), the potency of RP67580 and pattern 
of antagonism is different for the two agonists i . Thus, 
while RP67580 is an apparent competitive antagonist 
of NK 1 receptors with a pK b of 7.86 in the presence 
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Fig, 4. a: Agonist-directed receptor trafficking. One receptor (R) is coupled to two G proteins (G 1 and G2) each selectively activated by two different agonists 
{A 1 and A2) acting on the same receptor, b: Production of cAMP and inositol phosphate in LLC-PK1 cells transfected with a splice variant of the pituitary 
adenylate cyclase activating protein PACAP receptor in response to PACAP~7 (©), PACAP~_38 (11) and vasoactive intestinal peptide (E~). Data from Ref. 7. 
c: Reversal of intrinsic efficacy for dopamine receptor agonists activating dopamine D2 receptors in rat striatum and pituitary. Responses are shown as a 
function of receptor occupancy for quinpirole (©) and 3-(3-hydroxyphenyl)-N-n-propylpiperidine [(+}3-PPP] (O). Data from Ref. 8 
of substance P, it is an apparent uncompetitive antagonist 
with an apparent pK b of 8.9 in the presence of septide. 
When the possibility of heterogeneous receptors has been 
eliminated, it can then be proposed that he involvement of
different binding sites on the receptor for the two agonists 
may account for selective agonist blockade. In essence, one 
is still dealing with a heterogeneous receptor situation 
except that the 'receptors' in this case are binding regions 
2 3 6 TiPS -July 1995 (Vol. 16) 
P R I N C I P L E S 
a 120-] b 120]  
1 1001 ~ ~ 100]  I . I T I . - - - I~  
8oi ° 8oJ / 
=- .ol/N;  .0 4 
! o ~  o /  , , J o -~ 'e~Y , , 
-13 -12-11  -10  -9  -8  -7  -6  -5  -4  -13-12-11  -10  -9  -8  -7  -6  -5  -4  
Substance P (Ioglo M) Septide (Iog,o M) 
ARG1 ~ ~AR*G1 
c d ~- ,  ; / . ,  
/_. / / peptide /~/11 .'" 1 
N U [ / 14:1:1 AR -.. ' '" AR* / 
ARG2 IV,", AR G2 
RG2--, "" R'G2 
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on the same receptor macromolecule (Fig. 5c). Studies with 
site-directed mutagenesis in some receptor systems indicate 
disparities in the binding behaviour of peptides and small 
molecule antagonists. The most common interpretation f 
these data is that different portions of the receptor are pri- 
marly used for the binding of large peptides and small 
organic structures. There is an increasing database to 
support heterogeneous binding regions on the receptor 
macromolecules 16. 
Selective trafficking of receptors to different 
G proteins 
An alternative possibility to explain selective agonist 
blockade is that the differential antagonist potencies 
relate to the selective trafficking of receptors to different 
G proteins by agonists. This is a more complex hypoth- 
esis and requires that all of the ligands, including the an- 
tagonist, discern conformational states and coupling states 
of the receptor. For example, there are a number of 
possible relevant receptor species capable of producing a 
response for a single expressed receptor interacting with 
two G proteins (Fig. 5d). If two agonists directed the 
receptor to form different ternary complexes then a compli- 
cated scenario could ensue with differential blockade by 
antagonists that possess negative or positive efficacy. 
Under these circumstances, agonist-directed trafficking 
could make the response differentially sensitive to antag- 
onism by ligands that have either positive (weak partial 
agonists) or negative intrinsic efficacy (inverse agonists). 
An apparent weakness inthis hypothesis  the require- 
ment for coupling effects on antagonists, i.e. the antag- 
onist would require ither some positive or negative ffi- 
cacy. However, there is precedent for ligands with 
seemingly no efficacy in quiescent systems to have nega- 
tive efficacy in constitutively active receptor systems. Theo- 
retically, if conformational selection is a primary mech- 
anism for efficacy, then some efficacy (either positive or 
negative) for all ligands should be expected. This is 
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because the ligand would need to have identical affinity 
for R and R* not to exert some influence on subsequent 
coupling behaviour of the system. Under these circum- 
stances, ligand efficacy must be defined as the property 
of a molecule that affects ubsequent interaction of the 
receptor with other proteins 17. 
Differentiating between the two hypotheses 
Technically there are ways to differentiate he hypoth- 
eses of separate binding sites on the receptor and multiple 
G protein coupling. However, itis difficult o study these 
effects functionally because stimulus-response mechan- 
isms allow very small populations of receptor species to 
produce large responses; even though two agonists are 
both full agonists, they could be operating at different 
levels of receptor occupation. Therefore, binding studies 
are required. Radiolabelled versions of both agonists are 
necessary to allow comparison of saturation curves. If 
different sites on the same receptor were involved, then 
the maximal binding capacity for both agonists would be 
the same, whereas if different coupling were involved, the 
Bm~ x values might well differ. The latter hypothesis might 
indicate the existence of different sized pools of agonist 
ternary complexes since different pools of G protein com- 
peting for a single pool of receptor would be involved. 
Another approach to this would be to study the system 
under varying levels of receptor expression since this 
would change the receptor to G protein ratios. This would 
not affect a system in which the agonists bind to different 
portions of the same receptor, but it could affect a 
coupling mechanism since the stoichiometries would 
vary with changing expression level. 
Implications of agonist trafficking 
It is premature toconclude that agonists do or do not 
generally select multiple active receptor states. The bulk 
of the evidence indicates that many cases of selective stimu- 
lus production by agonists can be accounted for by the 
hypothesis of a single active receptor state produced in 
varying quantities by agonists of different intrinsic effi- 
cacy. However, the cases of reversal of relative potency of 
stimulus production cannot be explained by such an idea 
and the possibility of the more complex phenomenon f 
agonist-specific a tive receptor states must be considered. 
Such mechanisms have broad implications for the classifi- 
cation of receptors and drugs, and the screening of new 
chemical entities for therapeutic advantage. 
As discussed earlier, the possibility of agonist-selective 
receptor states uggests he possibility of agonist-selective 
potency of antagonists, if those antagonists have either 
positive or negative fficacy. If a situation is considered 
where two agonists such as acetylcholine and oxotremorine 
traffic muscarinic receptors to different G proteins, then 
it is possible that partial agonists for muscarinic receptors 
would show differential potency in terms of antagonism 
of the responses to these two agonists. This differential 
could vary across biological systems if the relative quan- 
tities of the different Gproteins involved varied with cell 
type. Thus, it would be conceivable that a given drug 
could be a more potent inhibitor of oxotremorine 
responses than acetylcholine r sponses in this situation, 
or vice versa. It is obvious that misleading results could 
be obtained if the wrong agonist is chosen for screening 
purposes. 
As with general statements regarding agonist raffick- 
ing, there are insufficient data to condude whether this is 
only a theoretical, ora real phenomenon. However, if this 
effect is operable in some receptor systems, it may be 
possible to design more selective agonists. If some ago- 
nists produce unwanted side-effects because of multiple 
G protein activation, then those side-effects could be 
potentially avoided by discovering agonists that direct 
signalling to more constructive pathways TM. 
Concluding remarks 
In conclusion, it can be shown that selective patterns of 
agonism can be produced from receptor selection by an 
agonist hat produces a uniform active state that then 
interacts with a complement of membrane G proteins in 
a homogeneous fa hion. However, there are also pharma- 
cological data that cannot be reconciled with such a 
scheme. These latter systems are of interest since they 
cannot easily be explained by simple receptor activation 
theories and thus may hold a key to a new understanding 
of the phenomenon f efficacy. 
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Chemical names 
McNA343: 4-(m-chlorophenylcarbamoyloxy)-2- 
butynyltrimethylammonium 
RP67580: 2-[1-imino-2-(2-methoxyphenyl)-ethyl]- 
Z7-diphenyl-4-perhydroisoindolone (3aR, 7aR) 
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